Investigation of the Relationship Between Central Sensitization and Neuropathic Pain in Lumbar Disc Herniation
Launched by MARMARA UNIVERSITY · Feb 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a condition called central sensitization (CS) affects pain in patients with lumbar disc herniation, which is a common back problem. Central sensitization means that the nervous system becomes overly sensitive, leading to increased pain even from normal activities. Researchers want to understand how this heightened sensitivity relates to the type and location of pain experienced by these patients.
To be eligible for this study, participants must have a diagnosis of lumbar disc herniation and agree to take part in the trial. Unfortunately, those with certain other conditions, such as active infections or diseases that cause nerve pain in the legs, cannot participate. If someone joins the study, they can expect to undergo assessments that will help the researchers learn more about their pain and how central sensitization may be influencing it. This research could lead to better understanding and treatment options for people suffering from chronic back pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Having a diagnosis of lumbar disc herniation Accepting to participate in the study
- Exclusion Criteria:
- • Concomitant active systemic inflammatory disease, infection and malignancy Having disease that will cause neuropathic pain in the other lower extremity, such as polyneuropathy, multiple sclerosis etc Refusing to participate in the study
About Marmara University
Marmara University is a distinguished academic institution located in Istanbul, Turkey, renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary approach, the university actively engages in the development and evaluation of new therapeutic interventions, fostering collaboration among researchers, clinicians, and industry partners. Marmara University’s focus on ethical standards and patient safety underscores its dedication to contributing valuable insights to the medical community and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Istanbul, Fevzi çakmak Mah, Muhsin Yazıcıoğlu Cd, Pendik, Turkey
Patients applied
Trial Officials
Canan Şanal Toprak, Asst.Prof
Study Chair
Marmara University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported